Breaking News Instant updates and real-time market news.

MACK

Merrimack

$6.35

0.09 (1.44%)

07:18
10/03/16
10/03
07:18
10/03/16
07:18

Merrimack announces 22% reduction in headcount, CEO Mulroy resigns

Merrimack Pharmaceuticals announced a major corporate restructuring with the objective of prioritizing its research and development on a focused set of systems biology-derived oncology products and strengthening its financial runway. As part of this move, Merrimack is immediately implementing a 22% reduction in headcount and eliminating more than $200M in expected costs over the next two years. In line with this restructuring, the Board of Directors has accepted the resignation of President and CEO Robert Mulroy, effective immediately. In order to accelerate this change, the Board of Directors has appointed Chairman of the Board Gary Crocker as interim President and CEO. "The Board is committed to focusing our resources. This major restructuring will allow us to strategically align our pipeline with our core capabilities and prioritize ongoing clinical development efforts while improving our financial flexibility," stated Crocker. "We believe this sharper focus will drive efficiency and innovation and promote the interests of not only our shareholders and employees, but also of cancer patients worldwide. The realization of shareholder value will become as intense a focus for Merrimack as our strength in innovation and development. The Board is convinced that there is tremendous inherent value within Merrimack that can be unlocked." In line with delivering the new goals of innovation and efficiency, John Dineen, Chairman of the Organization and Compensation Committee and former CEO of GE Healthcare, will lead the CEO search process. "We are grateful to Bob and acknowledge his leadership of Merrimack over the years," said Dineen. The reduction in personnel will not impact the commercial team or the execution of ONIVYDE's commercial launch and label expansion. "This strategic shift is designed to align our resources with the programs that have the greatest potential for disruptive change in the diagnosis and treatment of cancer, as well as to significantly increase our financial flexibility," said Dr. Yasir Al-Wakeel, CFO and Head of Corporate Development. He adds, "With the elimination of more than $200 million in expected expenses through research and development efficiencies, prioritization and cost containment over the next two years, today's announcement places Merrimack in a much stronger financial position." As a result, Merrimack now anticipates aggregate research and development and selling, general and administrative expenses in 2017 of approximately $190 million when calculated in accordance with GAAP, resulting in a cash runway that is expected to fund operations for at least the next 12 months based on cash on hand, anticipated near term milestones and reimbursements and ONIVYDE profits. This corresponds to a non-GAAP financial measure of $165 million of aggregate research and development and selling, general and administrative expenses in 2017 when excluding $25 million of anticipated milestone obligations to PharmaEngine, which are fully offset by corresponding milestone achievement obligations from Shire. A table reconciling guidance for aggregate research and development and selling, general and administrative expenses, excluding anticipated milestone obligations to PharmaEngine, a non-GAAP financial measure, to aggregate research and development and selling, general and administrative expenses calculated in accordance with GAAP is included at the end of this press release. The reduction in force was substantially completed on October 3rd and is expected to be fully completed by December 3rd. More information on the restructuring will be available in the Form 8-K to be filed by Merrimack. Merrimack plans to provide more financial and strategic details regarding the conclusion of this product prioritization process by the end of the fourth quarter.

MACK Merrimack
$6.35

0.09 (1.44%)

08/04/16
08/04/16
NO CHANGE

On The Fly: After Hours Movers
UP AFTER EARNINGS: Pacific Biosciences (PACB), up 17%... MasTec (MTZ), up 9.6%... Aratana Therapeutics (PETX), up 9.2%... Lion's Gate (LGF), up 6.4%... Priceline (PCLN), up 5.7%... Ubiquiti (UBNT), up 5.5%... MercadoLibre (MELI), up 4.1%... Organovo (ONVO), up 3.9%... Kraft Heinz (KHC), up 3.3%... EOG Resources (EOG), up 2.8%... Monster Beverage (MNST), up 1.2%... TASER (TASR), up 1.2%... Take-Two (TTWO), up 0.9%... Activision Blizzard (ATVI), up 1%... BioMarin (BMRN), up 0.4%. ALSO HIGHER: Egalet (EGLT), up 31.2% after the company announced that an FDA advisory committee recommended approval of its ARYMO ER drug... Rackspace (RAX), up 17.6% after the Wall Street Journal reported that the company was near a takeover deal with a private equity buyer... Osiris (OSIR), up 8.5% after it said that the manuscript from its prospective trial using Grafix was published. DOWN AFTER EARNINGS: Hortonworks (HDP), down 26.2%... PDL BioPharma (PDLI), down 17.5%... FireEye (FEYE), down 15.8%... Sierra Wireless (SWIR), down 15.6%... Aquinox (AQXP), down 14.7%... Zynga (ZNGA), down 9.4%... Universal Display (OLED), down 8.2%... Weight Watchers (WTW), down 7.6%... Zillow Group (Z, ZG), down 5.5%... Arista Networks (ANET), down 4.5%... Noodles & Company (NDLS), down 4.3%... Merrimack (MACK), down 1.7%... Bankrate (RATE), down 1.7%.
08/05/16
BMUR
08/05/16
NO CHANGE
Target $13
BMUR
Buy
Merrimack price target lowered to $13 from $16 at Brean Capital
Brean Capital lowered its price target on Merrimack to $13 from $16 following Q2 results. The firm cited the sales miss on Onivyde, although they are encouraged by its early launch. Brean Capital reiterated its Buy rating on Merrimack shares.
08/05/16
COWN
08/05/16
DOWNGRADE
COWN
Market Perform
Merrimack downgraded to Market Perform from Outperform at Cowen
08/19/16
BTIG
08/19/16
INITIATION
BTIG
Neutral
Merrimack initiated with a Neutral at BTIG
BTIG analyst Ling Wang initiated Merrimack with a Neutral as he expects shares to be range-bound given the likely slow ramp-up of ONIVYDE and data from MM-302 and MM-121 won't be available until 2017 or beyond;

TODAY'S FREE FLY STORIES

02:35
12/08/16
12/08
02:35
12/08/16
02:35
General news
FX Update: The dollar retained a generally softer bias »

FX Update: The dollar…

VNCE

Vince Holding

$4.55

0.35 (8.33%)

20:25
12/07/16
12/07
20:25
12/07/16
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Jan

NWBO

Northwest Biotherapeutics

$0.55

0.0227 (4.33%)

20:17
12/07/16
12/07
20:17
12/07/16
20:17
Hot Stocks
Northwest Biotherapeutics to delist from Nasdaq, confirms clinical trial plans »

Northwest Biotherapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$111.03

1.08 (0.98%)

, MSFT

Microsoft

$61.37

1.42 (2.37%)

20:07
12/07/16
12/07
20:07
12/07/16
20:07
Periodicals
NHL in negotiations to bring Apple devices to team benches, TSN says »

The NHL has told teams it…

AAPL

Apple

$111.03

1.08 (0.98%)

MSFT

Microsoft

$61.37

1.42 (2.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 13

    Mar

ATKR

Atkore

$19.71

-0.11 (-0.55%)

19:59
12/07/16
12/07
19:59
12/07/16
19:59
Syndicate
Atkore 8M share Secondary priced at $19.00 »

Credit Suisse, Deutsche…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

BPMC

Blueprint Medicines

$26.20

-2.23 (-7.84%)

19:58
12/07/16
12/07
19:58
12/07/16
19:58
Syndicate
Blueprint Medicines 5M share Secondary priced at $25.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

LULU

lululemon

$59.84

2.6 (4.54%)

19:50
12/07/16
12/07
19:50
12/07/16
19:50
Hot Stocks
lululemon CFO says early Q4 trends strengthened into December »

Speaking during the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Jan

LULU

lululemon

$59.84

2.6 (4.54%)

19:50
12/07/16
12/07
19:50
12/07/16
19:50
Hot Stocks
lululemon CEO highlights Q3 gross margin, reports 11% comp growth in pants »

Speaking during the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Jan

CVX

Chevron

$114.44

1.68 (1.49%)

19:20
12/07/16
12/07
19:20
12/07/16
19:20
Hot Stocks
Chevron announces $19.8B capital, exploratory budget for 2017 »

Chevron announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

X

U.S. Steel

$37.49

1.54 (4.28%)

18:49
12/07/16
12/07
18:49
12/07/16
18:49
Periodicals
U.S. Steel CEO: Company may bring back 10,000 U.S. jobs, CNBC says »

U.S. Steel could bring…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VNDA

Vanda

$15.40

-0.6 (-3.75%)

18:47
12/07/16
12/07
18:47
12/07/16
18:47
Hot Stocks
Vanda settles Fanapt patent litigation with Apotex »

Vanda Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AE

Adams Resources

$42.31

-0.68 (-1.58%)

, SWN

Southwestern Energy

$12.37

-0.08 (-0.64%)

18:46
12/07/16
12/07
18:46
12/07/16
18:46
Hot Stocks
Adams Resources appoints Josh Anders as CFO »

Adams Resources &…

AE

Adams Resources

$42.31

-0.68 (-1.58%)

SWN

Southwestern Energy

$12.37

-0.08 (-0.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EZPW

EZCORP

$11.80

0.05 (0.43%)

18:42
12/07/16
12/07
18:42
12/07/16
18:42
Earnings
EZCORP reports Q4 EPS with items (31c), may not compare to consensus 6c »

EPS figure includes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

RICE

Rice Energy

$24.59

-0.16 (-0.65%)

18:33
12/07/16
12/07
18:33
12/07/16
18:33
Initiation
Rice Energy initiated  »

Rice Energy initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$770.42

5.7 (0.75%)

18:30
12/07/16
12/07
18:30
12/07/16
18:30
Periodicals
Amazon spokesperson denies 2,000 grocery stores report, CNET says »

Following a report by the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ICON

Iconix Brand

$9.26

0.14 (1.54%)

18:23
12/07/16
12/07
18:23
12/07/16
18:23
Hot Stocks
Iconix Brand reports employment termination of Chief Strategy Officer Blumberg »

Iconix Brand disclosed in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBYI

Puma Biotechnology

$39.80

-2 (-4.78%)

18:23
12/07/16
12/07
18:23
12/07/16
18:23
Hot Stocks
Puma Biotechnology 'pleased' to complete biomarker analysis of neratinib »

Puma Biotechnology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTK

Flotek

$11.10

-2.01 (-15.33%)

18:17
12/07/16
12/07
18:17
12/07/16
18:17
Hot Stocks
Flotek: Reviewing FourWorld Capital short report, remain confident in product »

Speaking earlier during…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

PBYI

Puma Biotechnology

$39.80

-2 (-4.78%)

18:09
12/07/16
12/07
18:09
12/07/16
18:09
Hot Stocks
Puma Biotechnology 'pleased' with preliminary neratinib activity »

Puma Biotechnology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PNM

PNM Resources

$32.05

0.45 (1.42%)

18:09
12/07/16
12/07
18:09
12/07/16
18:09
Hot Stocks
PNM Resources requests an electric rate increase of $99M in New Mexico »

PNM Resources' New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

BK

BNY Mellon

$48.55

0.56 (1.17%)

18:03
12/07/16
12/07
18:03
12/07/16
18:03
Periodicals
BNY Mellon outage led to certain Swift payment failures, WSJ reports »

Bank of New York Mellon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLRD

Tailored Brands

$18.93

0.62 (3.39%)

17:52
12/07/16
12/07
17:52
12/07/16
17:52
Hot Stocks
Tailored Brands up 22% to $23.20 after Q3 results beat estimates »

The company also raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

FLXS

Flexsteel Industries

$59.12

2.92 (5.20%)

, UNH

UnitedHealth

$159.40

2.08 (1.32%)

17:50
12/07/16
12/07
17:50
12/07/16
17:50
Hot Stocks
Flexsteel names Eric Rangen chair of the board »

Flexsteel Industries…

FLXS

Flexsteel Industries

$59.12

2.92 (5.20%)

UNH

UnitedHealth

$159.40

2.08 (1.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NKE

Nike

$52.10

1.53 (3.03%)

, UA

Under Armour

$27.03

1.62 (6.38%)

17:49
12/07/16
12/07
17:49
12/07/16
17:49
Periodicals
Nike losing market share to faster-growing rivals, Barron's reports »

Despite being down nearly…

NKE

Nike

$52.10

1.53 (3.03%)

UA

Under Armour

$27.03

1.62 (6.38%)

ADDYY

adidas

$76.96

1.225 (1.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Dec

T

AT&T

$40.45

1.1 (2.80%)

17:45
12/07/16
12/07
17:45
12/07/16
17:45
Conference/Events
AT&T management to meet with Jefferies »

Group dinner to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

  • 07

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.